Get answers to common questions about support and resources from Genentech for patients who have been prescribed PERJETA.
Regardless of the type of health insurance your patients have – and even if they don't have any – there may be options available to help them afford PERJETA.
You can check patient eligibility online. The financial assistance tool will guide the patient through some of their options and let them know which financial support programs may be right for them.
Here are a few things you or your patient may need on hand:
Each program has its own time period in which eligible patients will receive assistance.
PERJETA Access Solutions may be able to help patients understand how to get the medicine they need. PERJETA Access Solutions can find out:
Even with health insurance, there may be concerns about the cost of treatment. PERJETA Access Solutions can refer patients to financial assistance options.
To learn more about potential financial assistance options, visit the Financial Assistance Options page.
Case Managers can help with PERJETA Access Solutions access, reimbursement and helping your patient get their prescribed medicine. For more information, please visit the PERJETA Case Manager page.
No matter what type of health insurance your patients have, and even if they have none at all, there may be options available to help afford PERJETA.
PERJETA Access Solutions is your resource for access and reimbursement support after PERJETA is prescribed. You can:
No. If the patient's health insurance plan denied coverage for PERJETA (after submission of a Prior Authorization, if required), the patient can apply for help from the Genentech Patient Foundation. The patient does not need to send proof of the appeal to get help.
Learn more about the Genentech Patient Foundation, including eligibility criteria and how to apply.
When a medical treatment is authorized by the patient’s insurance plan for a limited period of time, it will generally require reverification of coverage for continued treatment. PERJETA Access Solutions can help you obtain reverification for your patients.
PERJETA® (pertuzumab) is indicated for use in combination with Herceptin® (trastuzumab) and chemotherapy for
PERJETA® (pertuzumab) is indicated for use in combination with Herceptin® (trastuzumab) and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
PERJETA is contraindicated in patients with known hypersensitivity to pertuzumab or to any of its excipients
Left Ventricular Dysfunction (LVD)
Infusion-Related Reactions
Hypersensitivity Reactions/Anaphylaxis
Neoadjuvant Treatment of Breast Cancer
Adjuvant Treatment of Breast Cancer
Metastatic Breast Cancer
You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Please see full Prescribing Information for additional Important Safety Information, including BOXED WARNINGS.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.